Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab

Trial Profile

Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Capecitabine (Primary) ; Everolimus (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2018 Planned End Date changed from 28 Jun 2019 to 28 Jun 2020.
    • 07 Aug 2018 Planned primary completion date changed from 28 Jun 2018 to 28 Jun 2019.
    • 26 Apr 2018 Planned End Date changed from 1 Feb 2018 to 28 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top